Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Rahul Mannan

Showing results (51-60 of 89) with videos related to

Pageof 9
Sort By:
Neoplasia (New York, N.Y.)|February 3, 2025
Therapeutic benefit of the dual ALK/FAK inhibitor ESK440 in ALK-driven neuroblastomaSeema Chugh, Jean C Tien, Jennifer Hon, et al.
Histopathology|December 25, 2019
Clinicopathological characterisation of renal cell carcinoma in young adults: a contemporary update and review of literatureEman Abdulfatah, John M Kennedy, Khaled Hafez, et al.
The American Journal of Surgical Pathology|November 23, 2023
Hybrid Oncocytic Tumors (HOTs) in Birt-Hogg-Dubé Syndrome Patients-A Tale of Two Cities: Sequencing Analysis Reveals Dual Lineage Markers Capturing the 2 Cellular Populations of HOTXiao-Ming Wang, Rahul Mannan, Yuping Zhang, et al.
Cell Reports. Medicine|March 25, 2026
Targeting the ferritinophagy-lysosome axis as a therapeutic vulnerability in gastroenteropancreatic neuroendocrine tumorsYizhi Cao, Caleb Cheng, Yitong Yin, et al.
Medical Oncology (Northwood, London, England)|February 15, 2021
De novo neuroendocrine transdifferentiation in primary prostate cancer-a phenotype associated with advanced clinico-pathologic features and aggressive outcomeEman Abdulfatah, Zachery R Reichert, Matthew S Davenport, et al.
Human Pathology|December 29, 2022
Characterization of protein S-(2-succino)-cysteine (2SC) succination as a biomarker for fumarate hydratase-deficient renal cell carcinomaRahul Mannan, Xiaoming Wang, Pushpinder S Bawa, et al.
Biorxiv : the Preprint Server for Biology|April 8, 2024
p300/CBP degradation is required to disable the active AR enhanceosome in prostate cancerJie Luo, Zhixiang Chen, Yuanyuan Qiao, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 6, 2021
Virus-positive Merkel Cell Carcinoma Is an Independent Prognostic Group with Distinct Predictive BiomarkersKelly L Harms, Lili Zhao, Bryan Johnson, et al.
Nature Communications|June 29, 2022
The genetic heterogeneity and drug resistance mechanisms of relapsed refractory multiple myelomaJosh N Vo, Yi-Mi Wu, Jeanmarie Mishler, et al.
Science (New York, N.Y.)|June 26, 2025
Divergent FOXA1 mutations drive prostate tumorigenesis and therapy-resistant cellular plasticitySanjana Eyunni, Rahul Mannan, Yuping Zhang, et al.
Pageof 9

Showing results (51-60 of 89) with videos related to

Sort By:
Pageof 9
Neoplasia (New York, N.Y.)|February 3, 2025
Therapeutic benefit of the dual ALK/FAK inhibitor ESK440 in ALK-driven neuroblastomaSeema Chugh, Jean C Tien, Jennifer Hon, et al.
Histopathology|December 25, 2019
Clinicopathological characterisation of renal cell carcinoma in young adults: a contemporary update and review of literatureEman Abdulfatah, John M Kennedy, Khaled Hafez, et al.
The American Journal of Surgical Pathology|November 23, 2023
Hybrid Oncocytic Tumors (HOTs) in Birt-Hogg-Dubé Syndrome Patients-A Tale of Two Cities: Sequencing Analysis Reveals Dual Lineage Markers Capturing the 2 Cellular Populations of HOTXiao-Ming Wang, Rahul Mannan, Yuping Zhang, et al.
Cell Reports. Medicine|March 25, 2026
Targeting the ferritinophagy-lysosome axis as a therapeutic vulnerability in gastroenteropancreatic neuroendocrine tumorsYizhi Cao, Caleb Cheng, Yitong Yin, et al.
Medical Oncology (Northwood, London, England)|February 15, 2021
De novo neuroendocrine transdifferentiation in primary prostate cancer-a phenotype associated with advanced clinico-pathologic features and aggressive outcomeEman Abdulfatah, Zachery R Reichert, Matthew S Davenport, et al.
Human Pathology|December 29, 2022
Characterization of protein S-(2-succino)-cysteine (2SC) succination as a biomarker for fumarate hydratase-deficient renal cell carcinomaRahul Mannan, Xiaoming Wang, Pushpinder S Bawa, et al.
Biorxiv : the Preprint Server for Biology|April 8, 2024
p300/CBP degradation is required to disable the active AR enhanceosome in prostate cancerJie Luo, Zhixiang Chen, Yuanyuan Qiao, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 6, 2021
Virus-positive Merkel Cell Carcinoma Is an Independent Prognostic Group with Distinct Predictive BiomarkersKelly L Harms, Lili Zhao, Bryan Johnson, et al.
Nature Communications|June 29, 2022
The genetic heterogeneity and drug resistance mechanisms of relapsed refractory multiple myelomaJosh N Vo, Yi-Mi Wu, Jeanmarie Mishler, et al.
Science (New York, N.Y.)|June 26, 2025
Divergent FOXA1 mutations drive prostate tumorigenesis and therapy-resistant cellular plasticitySanjana Eyunni, Rahul Mannan, Yuping Zhang, et al.
Pageof 9